Trials / Terminated
TerminatedNCT00601861
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
Detailed description
The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant interleukin-21 | Fixed and equal dose for s.c. injection, 3 times weekly |
Timeline
- Start date
- 2008-02-13
- Primary completion
- 2008-06-25
- Completion
- 2008-06-25
- First posted
- 2008-01-28
- Last updated
- 2017-03-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00601861. Inclusion in this directory is not an endorsement.